US20100197962A1 - Use of Neboglamine in the Treatment of Toxicodependency - Google Patents
Use of Neboglamine in the Treatment of Toxicodependency Download PDFInfo
- Publication number
- US20100197962A1 US20100197962A1 US12/067,390 US6739006A US2010197962A1 US 20100197962 A1 US20100197962 A1 US 20100197962A1 US 6739006 A US6739006 A US 6739006A US 2010197962 A1 US2010197962 A1 US 2010197962A1
- Authority
- US
- United States
- Prior art keywords
- neboglamine
- use according
- pharmaceutically acceptable
- medicament
- induced
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- VCRGLZYPNNAVRP-JTQLQIEISA-N (4s)-4-amino-5-[(4,4-dimethylcyclohexyl)amino]-5-oxopentanoic acid Chemical compound CC1(C)CCC(NC(=O)[C@@H](N)CCC(O)=O)CC1 VCRGLZYPNNAVRP-JTQLQIEISA-N 0.000 title claims abstract description 44
- 229950007573 neboglamine Drugs 0.000 title claims abstract description 35
- 239000003814 drug Substances 0.000 claims abstract description 27
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims abstract description 23
- 229940079593 drug Drugs 0.000 claims abstract description 20
- 239000000203 mixture Substances 0.000 claims abstract description 12
- 229960003920 cocaine Drugs 0.000 claims abstract description 11
- 150000003839 salts Chemical class 0.000 claims abstract description 7
- 229940049706 benzodiazepine Drugs 0.000 claims abstract description 6
- 150000001557 benzodiazepines Chemical class 0.000 claims abstract description 5
- 239000000380 hallucinogen Substances 0.000 claims abstract description 5
- RHCSKNNOAZULRK-UHFFFAOYSA-N mescaline Chemical compound COC1=CC(CCN)=CC(OC)=C1OC RHCSKNNOAZULRK-UHFFFAOYSA-N 0.000 claims abstract description 5
- 238000002360 preparation method Methods 0.000 claims abstract description 5
- 239000000932 sedative agent Substances 0.000 claims abstract description 5
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 claims abstract description 4
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 claims abstract description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 4
- 229940125717 barbiturate Drugs 0.000 claims abstract description 4
- 229940127240 opiate Drugs 0.000 claims abstract description 4
- 239000000021 stimulant Substances 0.000 claims abstract description 3
- 240000004308 marijuana Species 0.000 claims abstract 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims abstract 2
- 235000013922 glutamic acid Nutrition 0.000 claims abstract 2
- 239000004220 glutamic acid Substances 0.000 claims abstract 2
- 230000001225 therapeutic effect Effects 0.000 claims description 5
- 239000011230 binding agent Substances 0.000 claims description 4
- 239000007884 disintegrant Substances 0.000 claims description 4
- 239000013543 active substance Substances 0.000 claims 3
- 238000013270 controlled release Methods 0.000 claims 3
- 239000000796 flavoring agent Substances 0.000 claims 3
- 235000003599 food sweetener Nutrition 0.000 claims 3
- 239000003906 humectant Substances 0.000 claims 3
- 239000005414 inactive ingredient Substances 0.000 claims 3
- 239000004615 ingredient Substances 0.000 claims 3
- 239000003755 preservative agent Substances 0.000 claims 3
- 238000001179 sorption measurement Methods 0.000 claims 3
- 239000003765 sweetening agent Substances 0.000 claims 3
- 239000003981 vehicle Substances 0.000 claims 3
- 230000001624 sedative effect Effects 0.000 claims 2
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 claims 1
- 229950010883 phencyclidine Drugs 0.000 claims 1
- 229940125723 sedative agent Drugs 0.000 abstract description 3
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 35
- 229960005181 morphine Drugs 0.000 description 18
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 16
- 230000001684 chronic effect Effects 0.000 description 11
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 10
- 229960003529 diazepam Drugs 0.000 description 10
- 238000007920 subcutaneous administration Methods 0.000 description 10
- 239000004471 Glycine Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 241000700159 Rattus Species 0.000 description 6
- 239000002504 physiological saline solution Substances 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 230000000949 anxiolytic effect Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 3
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 230000006742 locomotor activity Effects 0.000 description 3
- 230000037023 motor activity Effects 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 241000218236 Cannabis Species 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 208000013403 hyperactivity Diseases 0.000 description 2
- 230000003137 locomotive effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- NTCVVGBUOCVHTI-AXDSSHIGSA-N (4s)-2-amino-4-[(4,4-dimethylcyclohexyl)amino]pentanedioic acid Chemical compound CC1(C)CCC(N[C@@H](CC(N)C(O)=O)C(O)=O)CC1 NTCVVGBUOCVHTI-AXDSSHIGSA-N 0.000 description 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- 206010010219 Compulsions Diseases 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000000494 facilitatory effect Effects 0.000 description 1
- 230000000848 glutamatergic effect Effects 0.000 description 1
- 230000026781 habituation Effects 0.000 description 1
- 230000001660 hyperkinetic effect Effects 0.000 description 1
- 230000035873 hypermotility Effects 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000013016 learning Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
Definitions
- the present invention relates to a novel use of (S)-4-amino-N-(4,4-dimethylcyclohexyl)glutamic acid (CR 2249-neboglamine) (CAS Registry Number 163000-63-3), the racemic mixture thereof or a pharmaceutically acceptable salt thereof, for use in the treatment of toxicodependency induced by drugs such as Central Nervous System (CNS) sedatives such as opiates, benzodiazepines, barbiturates, alcohol, stimulants such as amphetamines and cocaine, and hallucinogens such as LSD, mescalin, cannabis (marijuana) or fencyclidine.
- CNS Central Nervous System
- psychological dependency means an irresistible impulse (compulsion) to continue self-administering the drug in order to find pleasure.
- the psychological dependency is the most important factor in their compulsive use.
- the term “physical dependency” means a state of habituation to the drug accompanied by tolerance and that is manifested by abstinence syndromes.
- Tolerance is the need to increase the dose of the drug in order to obtain the same effects as were initially obtained with lower doses; the abstinence syndrome is characterized by painful physical sensations that are manifested when the taking of the drug is stopped.
- CNS sedatives such as opiates, benzodiazepines, barbiturates and alcohol, which also all induce physical dependency and tolerance
- CNS stimulants for instance amphetamine and cocaine which induce physical dependency to a minor extent, if at all
- hallucinogens such as LSD, mescalin, cannabis (marijuana) and fencyclidine.
- neboglamine (CR 2249) has been shown to have significant modulatory properties on the glycine site (strychnine-insensitive) coupled to the NMDA receptor complex [Lanza et al., Neuropharmacology 36, 1057-64 (1997)], and also advantageous properties of promoting memory and learning in various animal models [Garofalo et al. J. Pharm. Pharmacol. 48, 1290-97 (1996)].
- the facilitatory activity exerted by neboglamine on the NMDA receptor complex should be of therapeutic use in conditions of glutamatergic hypo functionality.
- NMDA receptor complex may be involved in a variety of functional responses to cocaine, for instance locomotor activity, dependency (continued reinforcement of self-administration), tolerance and toxicity (Rockhold R. W., Progress in Drug Research 50: 155-92, 1998).
- glycine is capable of inhibiting the locomotor hyperactivity, tolerance and dependency induced by morphine in mice (K. W. Shin et al., Arch. Pharm. Res. 26: 1074-1078, 2003).
- neboglamine was evaluated in animal experimental models that may be considered as predictive for the evaluation of toxicodependency induced by various drugs such as cocaine, morphine and benzodiazepines, which are widely representative of the syndromes caused by toxicodependency.
- the motor activity was measured with a video camera and recorded using the Videotrack 512 system as described by Garofalo (J. Pharm. Pharmacol. 48: 1290-1297, 1996).
- Physiological saline, neboglamine (30 mg/kg) or glycine (300 mg/kg) were administered via the i.p. route 30 minutes before physiological saline, morphine (10 mg/kg s.c.) or cocaine (20 mg/kg s.c.).
- the locomotor activity was recorded for 15 minutes and the total distance covered (in cm) by the animal was recorded by the computer connected to the video camera. The results thus obtained are collated in Table 1.
- Neboglamine (30 mg/kg) or physiological saline were administered via the i.p. route 30 minutes before morphine (10 mg/kg s.c.) for 6 days. On the seventh day, the test was performed, as described in the preceding experiment, in comparison with a group of animals treated with the same dose of morphine given acutely only on the 7th day (final day of the, experiment). The results thus obtained are collated in Table 2.
- Chronic treatment with morphine induces an increase in the motor activity of the rat, compared with the acute effect of the drug, by about 50% (128.6% as opposed to 80.3%).
- Chronic pre-treatment with neboglamine (30 mg/kg i.p for 7 days) succeeds in almost completely antagonizing (70.8%) the development of the inverse tolerance induced by the chronic treatment with morphine.
- the rat placed in one of the closed quadrants, had free access to all 4 of the quadrants (2 open and 2 closed) for a period of 5 minutes.
- a compound with anxiolytic activity produces a percentage increase in the time spent in the free quadrants.
- Physiological saline 40 100.0 Acute diazepam (D) 5 105 262.5 Chronic diazepam (D-C) 5 ⁇ 2 ( ⁇ 7 days) + 5 (D) 58 145.0 Acute neboglamine (N) 30 51 127.0 Physiological (D-W) — 15 37.5 Neboglamine+ (D-C) 30 ⁇ 2 ( ⁇ 7 days) + 30 + 5 (D) 77 192.5 Neboglamine (D-W) — 44 110.0 Note: Physiological (D-W) is the group treated with diazepam for 7 days and retested 40 hours later with physiological saline. Neboglamine (D-W) is the group treated with diazepam and neboglamine for 7 days and retested 40 hours later with physiological saline
- Neboglamine displays non-significant anxiolytic activity (127% compared with the controls). However, its co-administration with diazepam does not reduce tolerance (192.5% effect compared with the control). In addition, the co-administration of neboglamine was shown to inhibit the abstinence crisis induced by stoppage of the chronic treatment with diazepam [110% of effect for the group N-(D-W) as opposed to 37.5% of effect for the group (D-W)].
- compositions comprising as active principle neboglamine or the racemic mixture thereof, in native form or pharmaceutically acceptable salts thereof.
- compositions for using the compounds according to the invention may be prepared using conventional techniques.
- the formulations include those suitable for oral use, for instance capsules, tablets, suspensions, emulsions, solutions; sterile solutions for parenteral use (including subcutaneous, intramuscular and intravenous administration), or preparations for topical or rectal use or other forms suitable for obtaining the desired therapeutic effect, for example solid formulations for oral use with delayed action, which allow a slow release of the active principle over time.
- Substances commonly used in the pharmaceutical field as excipients, binders, disintegrants and substances capable of stimulating transdermal absorption may be used together with the active principle in the pharmaceutical formulation.
- Neboglamine compounds such as the racemic mixture thereof, may thus be used in native form or as pharmaceutically acceptable salts.
- neboglamine it is preferably the sodium or potassium salt or the hydrochloride.
- the effective therapeutic amount of neboglamine to be used for the treatment of drug-induced toxicodependency should be between 10 and 600 mg and preferably from 30 to 300 mg per day of active principle, depending on the specific conditions of the treated patient, and the individual response to the treatment, the age and the weight of the patient.
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Addiction (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT000691A ITTO20050691A1 (it) | 2005-10-04 | 2005-10-04 | Uso di neboglamine nella terapia delle tossicodipendenze |
| ITTO2005A000691 | 2005-10-04 | ||
| PCT/IB2006/053603 WO2007039869A2 (en) | 2005-10-04 | 2006-10-03 | Use of neboglamine in the treatment of toxicodependency |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IB2006/053603 A-371-Of-International WO2007039869A2 (en) | 2005-10-04 | 2006-10-03 | Use of neboglamine in the treatment of toxicodependency |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US13/192,071 Division US8258185B2 (en) | 2005-10-04 | 2011-07-27 | Use of neboglamine in the treatment of toxicodependency |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US20100197962A1 true US20100197962A1 (en) | 2010-08-05 |
Family
ID=37814217
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US12/067,390 Abandoned US20100197962A1 (en) | 2005-10-04 | 2006-10-03 | Use of Neboglamine in the Treatment of Toxicodependency |
| US13/192,071 Expired - Fee Related US8258185B2 (en) | 2005-10-04 | 2011-07-27 | Use of neboglamine in the treatment of toxicodependency |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US13/192,071 Expired - Fee Related US8258185B2 (en) | 2005-10-04 | 2011-07-27 | Use of neboglamine in the treatment of toxicodependency |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20100197962A1 (ja) |
| EP (1) | EP1940376B1 (ja) |
| JP (1) | JP2009510158A (ja) |
| AT (1) | ATE425748T1 (ja) |
| AU (1) | AU2006298393B2 (ja) |
| CA (1) | CA2624449C (ja) |
| DE (1) | DE602006005831D1 (ja) |
| ES (1) | ES2323982T3 (ja) |
| IT (1) | ITTO20050691A1 (ja) |
| WO (1) | WO2007039869A2 (ja) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019147690A1 (en) * | 2018-01-23 | 2019-08-01 | High Sierra Technologies, Inc. | Cannabis products modified by removing volatile organic compounds and adding volatile unsaturated hydrocarbons |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5523323A (en) * | 1993-09-14 | 1996-06-04 | Maccecchini; Maria-Luisa | Use of partial agonists of the NMDA receptor to reduce opiate induced tolerance and dependence |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9024738D0 (en) * | 1990-11-14 | 1991-01-02 | Erba Carlo Spa | A new method of treatment of tumor necroisis factor(tnf)-related diseases |
| GB9109007D0 (en) * | 1991-04-26 | 1991-06-12 | Merck Sharp & Dohme | Therapeutic method |
| IT1264765B1 (it) * | 1993-03-10 | 1996-10-04 | Rotta Research Lab | Derivati dell'acido glutammico ed acido aspartico, procedimento per la loro preparazione e loro uso come farmaci potenzianti la |
| ITTO20040343A1 (it) * | 2004-05-24 | 2004-08-24 | Rotta Res Lab Spa | Uso di neboglamine (cr2249) come neuropsicotico e neuroprotettivo |
-
2005
- 2005-10-04 IT IT000691A patent/ITTO20050691A1/it unknown
-
2006
- 2006-10-03 AT AT06809478T patent/ATE425748T1/de not_active IP Right Cessation
- 2006-10-03 AU AU2006298393A patent/AU2006298393B2/en not_active Ceased
- 2006-10-03 JP JP2008534130A patent/JP2009510158A/ja active Pending
- 2006-10-03 US US12/067,390 patent/US20100197962A1/en not_active Abandoned
- 2006-10-03 ES ES06809478T patent/ES2323982T3/es active Active
- 2006-10-03 CA CA2624449A patent/CA2624449C/en not_active Expired - Fee Related
- 2006-10-03 DE DE602006005831T patent/DE602006005831D1/de active Active
- 2006-10-03 WO PCT/IB2006/053603 patent/WO2007039869A2/en active Application Filing
- 2006-10-03 EP EP06809478A patent/EP1940376B1/en not_active Not-in-force
-
2011
- 2011-07-27 US US13/192,071 patent/US8258185B2/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5523323A (en) * | 1993-09-14 | 1996-06-04 | Maccecchini; Maria-Luisa | Use of partial agonists of the NMDA receptor to reduce opiate induced tolerance and dependence |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019147690A1 (en) * | 2018-01-23 | 2019-08-01 | High Sierra Technologies, Inc. | Cannabis products modified by removing volatile organic compounds and adding volatile unsaturated hydrocarbons |
| US10737198B2 (en) | 2018-01-23 | 2020-08-11 | High Sierra Technologies, Inc. | Cannabis products modified by removing volatile organic compounds and adding volatile unsaturated hydrocarbons |
| US10835839B1 (en) | 2018-01-23 | 2020-11-17 | High Sierra Technologies, Inc. | Cannabis products modified by removing volatile organic compounds and adding volatile unsaturated hydrocarbons |
| US11338222B2 (en) | 2018-01-23 | 2022-05-24 | High Sierra Technologies, Inc. | Cannabis products modified by removing volatile organic compounds and adding volatile unsaturated hydrocarbons |
Also Published As
| Publication number | Publication date |
|---|---|
| ES2323982T3 (es) | 2009-07-28 |
| ITTO20050691A1 (it) | 2007-04-05 |
| EP1940376B1 (en) | 2009-03-18 |
| WO2007039869A2 (en) | 2007-04-12 |
| AU2006298393B2 (en) | 2011-04-14 |
| WO2007039869A3 (en) | 2007-07-05 |
| DE602006005831D1 (de) | 2009-04-30 |
| AU2006298393A1 (en) | 2007-04-12 |
| ATE425748T1 (de) | 2009-04-15 |
| CA2624449C (en) | 2013-12-17 |
| US20110288173A1 (en) | 2011-11-24 |
| US8258185B2 (en) | 2012-09-04 |
| EP1940376A2 (en) | 2008-07-09 |
| JP2009510158A (ja) | 2009-03-12 |
| CA2624449A1 (en) | 2007-04-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5698282B2 (ja) | 痛みの治療のための混合されたＯＲＬ１／μ−アゴニスト | |
| JP5411504B2 (ja) | 薬物嗜癖および行動嗜癖を治療するためのイブジラストの使用 | |
| DK2224917T3 (en) | Composition with nicotine and opipramol and its use | |
| US20070099947A1 (en) | Methods and compositions for the treatment of brain reward system disorders by combination therapy | |
| US20020037925A1 (en) | Treatment of addiction and addiction-related behavior | |
| JP2002532393A (ja) | エキソ−ｒ−メカミラミン製剤および治療におけるその使用 | |
| ES2236551T3 (es) | Combinacion de principios activos para el tratamiento medico de toxicomanias. | |
| BRPI0610663A2 (pt) | uso terapêutico de nefopam e seus análogos | |
| JPS59501459A (ja) | カフェインを含んで成る改良された鎮痛及び抗炎症組成物並びにその使用方法 | |
| US20110224245A1 (en) | Treatment Of Neurological Disorders Using Huperzine | |
| US8258185B2 (en) | Use of neboglamine in the treatment of toxicodependency | |
| US5547956A (en) | Pharmaceutical composition and the method for treating drug addicts' withdrawal syndromes and detoxifying addicts by the same | |
| KR20180033201A (ko) | 진해 조성물 및 방법 | |
| US20150110865A1 (en) | Cns stimulant and opioid receptor antagonist combination as a non-addictive, non-aversive and synergistic anti-obesity treatment | |
| CN112569237B (zh) | 伊马替尼及其衍生物与尼古丁或其类似物联用或复方在防治尼古丁成瘾与复吸中的应用 | |
| ES2285995T3 (es) | Combinacion para el tratamiento de la depresion y ansiedad que contiene un antagonista del receptor de nk-1 que penetra en el snc y un agente antidepresivo o ansiolitico. | |
| KR20220113411A (ko) | KV7 칼륨 채널 개방제(opener)의 통증 치료를 위한 용도 | |
| WO2021063387A1 (zh) | 伊马替尼及其衍生物的组合物在制备预防、治疗及防治成瘾复吸药物中的应用 | |
| US8779003B2 (en) | Method and composition for prolonging analgesic effect of local anesthetic | |
| EA003557B1 (ru) | Схема обезболивания | |
| CN112569355B (zh) | 伊马替尼及其衍生物与成瘾物质联合用药或复方制剂在预防、治疗成瘾及防治复吸中的应用 | |
| WO2010025251A2 (en) | Materials and methods for modulating appetite, weight gain and adhd using varenicline | |
| CN116421611A (zh) | 酸枣仁皂苷在制备镇痛药物/减少成瘾性的药物中的应用 | |
| Walsh | Antihistamines (H1 receptor antagonists) | |
| US8142800B1 (en) | Oral high potency clinical anti-craving treatment and method of use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: ROTTAPHARM S.P.A., ITALY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MAKOVEC, FRANCESCO;CASELLI, GIANFRANCO;ROVATI, LUCIO CLAUDIO;AND OTHERS;REEL/FRAME:024976/0509 Effective date: 20080430 |
|
| STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |